ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Biologics"

  • Abstract Number: 183 • 2020 Pediatric Rheumatology Symposium

    Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship

    Alaina Linafelter1, Julia Harris 2, Rob Herr 1, Stephanie Quinn 1 and Ashley Cooper 3, 1Children's Mercy Kansas City, Kansas City, Missouri, 2Children's Mercy Kansas City, Overland Park, 3Children's Mercy Kansas City, Kansas City

    Background/Purpose: Biologic medications are commonly utilized to treat pediatric rheumatic diseases.  Being high-cost, most third-party payors require dispensing through a specialty pharmacy.  Common challenges with…
  • Abstract Number: L12 • 2019 ACR/ARP Annual Meeting

    Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study

    Evgeniy Nasonov 1, Saeed Fatenejad 2, Elena Korneva 3, Diana Krechikova 4, Alexey Maslyansky 5, Tatyana Plaksina 6, Marina Stanislav 7, Rumen Stoilov 8, Tamara Tyabut 9, Sergey Yakushin 10, Elena Zonova 11 and Mark Genovese12, 1FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, 2SFC Medica, Charlotte, North Carolina, 3R-Pharm, Moscow, Russia, 4Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, 5SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, 6SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, 7V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, 8UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, 9Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, 10Ryazan State Medical University, Ryazan, Russia, 11Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, 12Stanford University, Stanford, CA

    Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: 259 • 2019 ACR/ARP Annual Meeting

    Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty

    Joseph Tkacz 1, Ervant Maksabedian2, Philip Chan 1, Brendan Limone 1, Alexis Ogdie 3, Elaine Karis 4 and Bradley Stolshek 2, 1IBM Watson, Bethesda, MD, 2Amgen Inc., Thousand Oaks, CA, 3University of Pennsylvania, Philadelphia, PA, 4Amgen Inc, Thousand Oaks, CA

    Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…
  • Abstract Number: 1818 • 2019 ACR/ARP Annual Meeting

    Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study

    Laura Coates1, Sreekumar Pillai 2, Lu Zhang 2, David Adams 2, Lisa Kerr 2, Maja Hojnik 2, Gaia Gallo 2, Ivo Valter 3, Hasan Tahir 4, Vinod Chandran 5, Philip Mease 6 and Arthur Kavanaugh 7, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Eli Lilly and Company, Indianapolis, IN, 3Center for Clinical and Basic Research, Tallinn, Estonia, 4Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, 5Division of Rheumatology, University of Toronto, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 6Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 7University of California, San Diego School of Medicine, La Jolla, CA

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that may lead to serious disability if not appropriately treated. Data on the effect of treatment…
  • Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting

    Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis

    Daniah Basodan1, Kathleen M Andersen 2, Xintong Li 3, Jeffrey Curtis 4 and G. Caleb Alexander 5, 1University of Alberta, Edmonton, AB, Canada, 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, 3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 4University of Alabama at Birmingham, Birmingham, AL, 5Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD

    Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…
  • Abstract Number: 526 • 2019 ACR/ARP Annual Meeting

    Factors Influencing Discontinuation in Long-term RA Treatment

    Madison Grinnell1, Sofia Pedro 2 and Kaleb Michaud 3, 1University of Nebraska College of Medicine, OMAHA, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: While medication persistence can act as a substitute metric for effectiveness, few studies have examined real-world patterns of bDMARD persistence by line of treatment…
  • Abstract Number: 1836 • 2019 ACR/ARP Annual Meeting

    Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial

    Robert Spiera1, Sebastian Unizony 2, Min Bao 3, Yves Luder 4, Páris Sidiropoulos 3, Jian Han 3, Jinglan Pei 3 and John Stone 2, 1Hospital for Special Surgery, New York, NY, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 3Genentech, South San Francisco, CA, 4F. Hoffmann-La Roche, Basel, Switzerland

    Background/Purpose: GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).1 Growing evidence…
  • Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

    Philip Mease1, Laure Gossec 2, Laura Coates 3, Alice B. Gottlieb 4, Deepak Assudani 5, Barbara Ink 5, Jason Coarse 6, Oscar Irvin-Sellers 5 and Dafna Gladman 7, 1Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 2Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 3University of Oxford, Oxford, United Kingdom, 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, 5UCB Pharma, Slough, UK, Slough, United Kingdom, 6UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 7Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

    Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
  • Abstract Number: 849 • 2019 ACR/ARP Annual Meeting

    Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database

    Raphaèle Seror1, Alexandre Lafourcade 2, yann De Rycke 2, Bruno Fautrel 3, Xavier Mariette 4 and Florence Tubach 5, 1Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, 2Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, 3Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France

    Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
  • Abstract Number: 2097 • 2019 ACR/ARP Annual Meeting

    Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis

    Ufuk İlgen1, Sezin Turan 1, Hakan Emmungil 1, Alper Sarı 2, Abdulsamet Erden 2, Levent Kilic 3, Ömer Karadağ 2, Sedat Kiraz 3, Ali İhsan Ertenli 4, Orhan Küçükşahin 5, Şükran Erten 6, Zeynel Abidin Akar 7, Burak Öz 7, Süleyman Serdar Koca 8, Cemal Bes 9, Nilufer Alpay-Kanitez 10, Emre Tekgöz 11, Seda Çolak 11, Muhammet Çınar 11, Sedat Yılmaz 11, Veli Yazısız 12, Mustafa Ender Terzioğlu 12, Ayşe Bahar Keleşoğlu Dinçer 13, Aşkın Ateş 13, Rıdvan Mercan 14, Onay Gercik 15, Servet Akar 16, Mehmet Pamir Atagündüz 17, Gezmiş Kimyon 18, Emel Gönüllü 19, Emine Duygu Ersözlü 20, Müge Aydın Tufan 21, Burcu Yağız 22, Belkıs Nihan Coşkun 23, Yavuz Pehlivan 22, Ediz Dalkılıç 22 and Umut Kalyoncu 24, 1Trakya University, Edirne, Turkey, 2Hacettepe University, Ankara, Turkey, 3Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 4Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 5Liv Hospital, Ankara, Turkey, 6Yıldırım Beyazıt University, Ankara, Turkey, 7Fırat University, Elazığ, Turkey, 8Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, 9University of Medical Sciences, İstanbul, Turkey, 10Koc University School of Medicine, Division of Rheumatology, İstanbul, Turkey, 11University of Medical Sciences, Ankara, Turkey, 12Akdeniz University, Antalya, Turkey, 13Ankara University, Ankara, Turkey, 14Namık Kemal University, Tekirdağ, Turkey, 15Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 16Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 17Marmara University, İstanbul, Turkey, 18Mustafa Kemal University, Hatay, Turkey, 19Sakarya University, Sakarya, Turkey, 20Adana State Hospital, Adana, Turkey, 21Başkent University, Adana, Turkey, 22Uludağ University, Bursa, Turkey, 23Uludağ University, Bursa, 24Hacettepe University Department of Rheumatology, Ankara, Turkey

    Background/Purpose: Screening for and the treatment of latent tuberculosis is recommended in patients with inflammatory arthritides prior to biologic treatments, particularly the TNF inhibitors. The…
  • Abstract Number: 894 • 2019 ACR/ARP Annual Meeting

    Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015

    Miao Jiang 1, Barnabas Desta 1, Aimee Near 2, Xia Wang 1 and Edward Hammond1, 1AstraZeneca, Gaithersburg, MD, 2IQVIA, Durham, NC

    Background/Purpose: We evaluated the real-world frequency and severity of flares and associated costs 1 year post diagnosis in a US cohort with newly diagnosed SLE.Methods:…
  • Abstract Number: 2253 • 2019 ACR/ARP Annual Meeting

    Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis

    Patrick Webster1, Nicole Wilson 2, Christina Payne 1, Kelly Shields 3 and Tarun Sharma 1, 1Allegheny Health Network, Pittsburgh, PA, 2Medicine Institute Research, Bioinformatics, Pittsburgh, PA, 3Highmark Data Science, Pittsburgh

    Background/Purpose: The 2015 American College of Rheumatology (ACR) and 2013 European League Against Rheumatology (EULAR) guidelines for management of rheumatoid arthritis (RA) conditionally recommend consideration…
  • Abstract Number: 937 • 2019 ACR/ARP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

    Désirée van der Heijde1, Lianne Gensler 2, Atul Deodhar 3, Xenofon Baraliakos 4, Denis Poddubnyy 5, Alan Kivitz 6, Marga Oortgiesen 7, Dominique Baeten 8, Nadine Goldammer 9, Jason Coarse 7, MK Farmer 7 and Maxime Dougados 10, 1Leiden University Medical Center, Leiden, Netherlands, 2University San Francisco California, San Francisco, CA, 3Oregon Health & Science University, Portland, OR, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 6Altoona Center for Clinical Research, Duncansville, PA, 7UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 8UCB Pharma, Brussels, Belgium, Brussels, 9UCB Pharma, Monheim, Germany, Monheim, Germany, 10Cochin Hospital, Paris, France

    Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
  • 1
  • 2
  • 3
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences